Variable No of patients % of total
Age, years (median, 61 years) ≤ 60 >60 11 13 45.8% 54.2%
Performance status ECOG 0 ECOG 1-2 20 5 83.4% 16.6%
Menopausal status Pre- Post- 7 17 29.2% 70.8%
Tumour histology Ductal carcinoma Lobular carcinoma Other 20 2 2 83.4% 8.3% 8.3%
Histologic grade G1-G2 G3         6 18 25% 75%
Ki-67 (median 60%) ≤ 20% >20% 7 17  29.2% 70.8%
Lympho-vascular invasion Yes No 9 15 37.5% 62.5%
Necrosis Yes No   5 19 20.8% 79.2%
AR Positive Negative 8 16 33% 67%
Type of surgery Quadrantectomy Radical mastectomy 10 14 41.7% 58.3%
(Neo)adjuvant chemotherapy CMF/CMFLike Antracyclines Antracyclines and taxanes No 5 8 10 1 20.8% 33% 41.7% 4.5%
Visceral disease Yes No 19 5 7.2% 20.8%
Number of metastatic sites <3 ≥ 3 16 8 67% 33%
First-line chemotherapy Antracyclines-based Taxanes-based Platinum-based Other 5 12 6 6 20.8% 50% 33% 33%
First-line chemotherapy Single-agent Combination of drugs 10 14 41.7% 58.3%
Table 1: Baseline characteristics of 24 patients.